Bill Behnke’s Post

ATTN #BIO2024: Today at 2:30 pm, our CEO, Bob Linke, gives a company presentation about OSM-0205, our lead product. We look forward to providing an update on our plans for OSM-0205, which is poised to initiate clinical development later this year. OSM-0205 is a preventative treatment to help patients avoid the painful and debilitating effects of chemotherapy-induced peripheral neuropathy (CIPN), common amongst taxane-based chemotherapies, including the leading breast cancer chemotherapy treatment. CIPN affects as many as 80% of these cancer patients and can significantly impact both quality of life and survival. Stop by to see our company presentation or request a meeting with our CEO, Bob Linke through, the Biotechnology Innovation Organization (BIO) One-on-One Partnering™ System: https://lnkd.in/eEDtKaAK #oncology #biotech #investors

🚀 Exciting News! 🚀 We are thrilled to announce that our portfolio company, iOnctura, has closed a EUR 80 million Series B round! Led by Syncona Limited and the European Investment Council, this funding will drive the late-stage development of treatments for hard-to-treat cancers. Since our initial investment in 2019, iOnctura's team has delivered exceptional proof-of-concept data for its drug candidates, roginolisib and cambritaxestat, in rare tumors with high unmet needs. With this new financing, roginolisib will be tested in broader trials for uveal melanoma, non-small cell lung cancer, and primary myelofibrosis, while cambritaxestat will advance for fibrotic cancers like metastatic pancreatic cancer. We are excited to welcome new investors and continue supporting iOnctura as it brings these critical treatments closer to patients in need. #Biotech #Investment #CancerTreatment #Pharma #Innovation #HealthTech #SeriesBRound #iOnctura #EuropeanInvestmentCouncil #Inkef

#fundingalert 💼Company: NextPoint Therapeutics, Inc. 💰Funding: $42.5Million  ⚡Round: Series B 👥Investors: Catalio Capital Management, R. Jacob Vogelstein, MPM BioImpact, Leaps by Bayer, Sixty Degree Capital, Dana-Farber Cancer Institute NextPoint was founded by Ivan Cheung (CEO). The funds will be used to advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional #therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Their innovative approach integrates #foundational science with a defined #clinical biomarker strategy to deliver a new class of #monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Read more - https://lnkd.in/gx5rqfVC To share your startup story write us on - [email protected] #nextPoint #funding #startup

#Epigenetics Market Envisions Notable CAGR Growth in the Years 2023–2032 https://lnkd.in/drVjVNMv Epigenetics Epigenetics and Cell Fate Centre Epigenetics International THE EPIGENETICS HEALING CENTER, LLC Cancer Epigenetics Society Max Planck Institute of Immunobiology and Epigenetics Zenith Epigenetics Ltd. Everything Epigenetics Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC) Penn Epigenetics Institute Celgene E3:Engaging Epigenetics Experts MarketsandMarkets Epigenetics Congress Lunasin and Nutritional Epigenetics Conscious Epigenetics Novus International, Inc. Zymo Research Corp Tune Therapeutics HudsonAlpha Institute for Biotechnology Constellation Pharmaceuticals, A MorphoSys Company Eurofins Discovery New England Biolabs Dovetail Genomics Active Motif Omega Therapeutics Fountain Life Eurofins DiscoverX MBL International Corporation Chroma Medicine #Epigenetics #biotechnology #business_opportunities #marketanalysis #marketresearch #opportunities #business #future 

Today, on average, it takes over 10 years and costs billions of dollars to develop a new drug. At Physiomics, we harness cutting-edge mathematical modelling to help our partners accelerate the journey of bringing great cancer drugs to market, making it faster and more cost-effective. By using sophisticated in silico techniques to predict how potential drugs interact within the body, we aim to reduce the reliance on time-consuming lab work and animal studies. 🚀 Our team of scientists are here to help you navigate the challenges of developing breakthrough cancer drugs, from the early stages of discovery through to clinical application. Reach out to learn how our proven solutions can help you accelerate your drug development efforts! #Cancer #DrugDevelopment #CancerDrugs #CancerSimulation #InSilico #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #TranslationalModelling #PYC

We're thrilled to announce the publication of groundbreaking research on narazaciclib and its anti-AML activity in preclinical models with specific AML mutations of clinical significance. This collaboration between Hanx Biopharmaceuticals, Crown Bioscience, and other cancer researchers has revealed promising results in targeting and inhibiting key kinases involved in AML. Dive deeper into our findings and discover how our collaborative efforts are contributing to treatments for AML. ➡️ https://bit.ly/3UrLjH7 #OncologyResearch #DrugDevelopment #AcuteMyeloidLeukemia

#Epigenetics Market Envisions Notable CAGR Growth in the Years 2023–2032 https://lnkd.in/drVjVNMv Growing prevalence of #cancer and #cardiovascular #diseases is the driving the #epigenetics #market. Increasing adoption of epigenetics drugs as an alternative #treatment to the #conventional cancer #treatment is further fueling the #growth of the epigenetics market. Merck KGaA, Darmstadt, Germany Illumina PacBio abcam Active Motif Bio-Rad Laboratories Promega Corporation PerkinElmer QIAGEN New England Biolabs Zymo Research Corp Diagenode, a Hologic company F. Hoffmann-La Roche Ltd #Epigenetics #biotechnology #business_opportunities #marketanalysis #marketresearch #opportunities #business #future 

#Epigenetics Market Forecast 2023 to 2032 | Covid 19 Impact And Recovery. >> https://lnkd.in/drVjVNMv Epigenetics Epigenetics and Cell Fate Centre Epigenetics International THE EPIGENETICS HEALING CENTER, LLC Cancer Epigenetics Society Max Planck Institute of Immunobiology and Epigenetics Zenith Epigenetics Ltd. Everything Epigenetics Canadian Epigenetics, Environment and Health Research Consortium (CEEHRC) Penn Epigenetics Institute Celgene E3:Engaging Epigenetics Experts MarketsandMarkets Epigenetics Congress Lunasin and Nutritional Epigenetics Conscious Epigenetics Novus International, Inc. Zymo Research Corp Tune Therapeutics HudsonAlpha Institute for Biotechnology Constellation Pharmaceuticals, A MorphoSys Company Eurofins Discovery New England Biolabs Dovetail Genomics Active Motif Omega Therapeutics Fountain Life Eurofins DiscoverX MBL International Corporation Chroma Medicine #Epigenetics #biotechnology #business_opportunities #marketanalysis #marketresearch #opportunities #business #future 

#Epigenetics Market Forecast 2023 to 2032 | Covid 19 Impact And Recovery. >> https://lnkd.in/drVjVNMv Growing prevalence of #cancer and #cardiovascular #diseases is the driving the #epigenetics #market. Increasing adoption of epigenetics drugs as an alternative #treatment to the #conventional cancer #treatment is further fueling the #growth of the epigenetics market. Merck KGaA, Darmstadt, Germany Illumina PacBio abcam Active Motif Bio-Rad Laboratories Promega Corporation PerkinElmer QIAGEN New England Biolabs Zymo Research Corp Diagenode, a Hologic company F. Hoffmann-La Roche Ltd #Epigenetics #biotechnology #business_opportunities #marketanalysis #marketresearch #opportunities #business #future 

Rakovina Therapeutics Announces Strategic Pivot to AI Using a platform powered by advanced AI algorithms, Rakovina can quickly analyze billions of molecular structures to evaluate their potential as targeted cancer drugs. This approach is innovative for developing new drug therapies that target DNA-damage response-related vulnerabilities that are common in many types of cancer. READ HERE: https://lnkd.in/gvT999iJ #biotech #oncology #biotechnews #medicalscience #medtech #technology #AI #AInews #technews #cancerresearch #stocks